Automated VMAT2 [18F]AV-133 PET analysis in Parkinson’s disease
Objective: To evaluate a fully automated image analysis pipeline to process vesicular monoamine transporters type 2 (VMAT2) [18F]AV-133 tracer positron emission tomography (PET) images, by…Altered brain energetics in Parkinson’s Disease: a multimodal neuroimaging study
Objective: To investigate patterns of altered brain energetics in Parkinson’s disease (PD). Background: Alterations in mitochondrial function, related to brain energetics, may play an important…Relevance of amyloid deposition for REM sleep behavior disorder in Parkinson’s disease
Objective: In this study, we aimed to investigate the relationship between regional [18F]florbetaben PET binding to amyloid-β (Aβ) and REM sleep behavior disorder (RBD) in…Progression of striatocortical dysfunction in Parkinson’s disease: a longitudinal combined PET and fMRI study
Objective: To investigate the longitudinal progression of striatal dopaminergic dysfunction and its consequences on functional connectivity (FC) networks and clinical progression in Parkinson's disease (PD)…Cerebral Topography of [11C]-Flumazenil GABAA Receptor Expression in Parkinson’s Disease Fallers and Freezers
Objective: To examine the cerebral topography of GABAA Receptor Expression in Parkinson’s Disease (PD) Fallers and Freezers. Background: Episodic mobility disturbances, like falls and freezing…In vivo positive amyloid PET in a patient with PDD, always reliable?
Objective: To describe a singular case of an early-onset Parkinson disease (PD) patient with PD dementia who presented in vivo positive 18 F-Flutebetamol PET but…Imaging the noradrenergic system in Parkinson’s disease: A [11C]Yohimbine PET and neuromelanin MRI study
Objective: To assess two aspects of the noradrenergic system using multimodal in vivo imaging in a sample of Parkinson’s disease (PD) patients and healthy controls…Network analysis of brain perfusion in [11C]UCB-J PET: Parkinson’s related motor pattern (PDRP)
Objective: The aim was to investigate the use of R1 (relative delivery parameter) as a surrogate of blood perfusion to identify brain networks specific to…Quantification of Striatal and Extrastriatal Dopamine Transporters with [18F]PR04.MZ and [18F] PI- 2620 PET in Patients with Progressive Supranuclear Palsy.
Objective: We aim to evaluate the differences in striatal subregional dopamine transporter loss between Parkinson disease (PD) and progressive supranuclear palsy (PSP) of any stage…18F-Florzolotau PET Imaging Captures the Distribution Patterns and Regional Vulnerability of Tau Pathology in Progressive Supranuclear Palsy
Objective: This study aimed to investigate whether 18F-Florzolotau PET imaging may capture the distribution patterns and regional vulnerability of tau pathology in PSP, and to…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 33
- Next Page »